Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Navar

Showing results (571-580 of 711) with videos related to

Pageof 72
Sort By:
JAMA Cardiology|October 4, 2017
Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor TherapyAnn Marie Navar, Benjamin Taylor, Hillary Mulder, et al.
Circulation|December 28, 2018
Quantifying Importance of Major Risk Factors for Coronary Heart DiseaseMichael J Pencina, Ann Marie Navar, Daniel Wojdyla, et al.
American Journal of Preventive Cardiology|July 30, 2021
County-level phenomapping to identify disparities in cardiovascular outcomes: An unsupervised clustering analysis: Short title: Unsupervised clustering of counties and risk of cardiovascular mortalityMatthew W Segar, Shreya Rao, Ann Marie Navar, et al.
JAMA Cardiology|July 20, 2016
Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United StatesJerry C Lee, Tomasz Zdrojewski, Michael J Pencina, et al.
American Heart Journal|September 20, 2015
Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular eventsMin Jung Ko, Yun Jung Kim, Chan Mi Park, et al.
Pharmacoepidemiology and Drug Safety|December 11, 2021
Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapiesSara N Levintow, Kate K Orroth, Alexander Breskin, et al.
Federation Proceedings|December 1, 1986
Direct assessment of renal microcirculatory dynamicsL G Navar, J P Gilmore, W L Joyner, et al.
Clinical Cardiology|June 5, 2021
Prospective evaluation of lipid management following acute coronary syndrome in non-Western countriesAnn Marie Navar, Simon T Matskeplishvili, Miguel Urina-Triana, et al.
American Journal of Physiology. Renal Physiology|November 27, 2015
Vasopressin/V2 receptor stimulates renin synthesis in the collecting ductAlexis A Gonzalez, Flavia Cifuentes-Araneda, Cristobal Ibaceta-Gonzalez, et al.
American Heart Journal|December 12, 2017
Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) projectPaul L Hess, Kevin Kennedy, Michael Cowherd, et al.
Pageof 72

Showing results (571-580 of 711) with videos related to

Sort By:
Pageof 72
JAMA Cardiology|October 4, 2017
Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor TherapyAnn Marie Navar, Benjamin Taylor, Hillary Mulder, et al.
Circulation|December 28, 2018
Quantifying Importance of Major Risk Factors for Coronary Heart DiseaseMichael J Pencina, Ann Marie Navar, Daniel Wojdyla, et al.
American Journal of Preventive Cardiology|July 30, 2021
County-level phenomapping to identify disparities in cardiovascular outcomes: An unsupervised clustering analysis: Short title: Unsupervised clustering of counties and risk of cardiovascular mortalityMatthew W Segar, Shreya Rao, Ann Marie Navar, et al.
JAMA Cardiology|July 20, 2016
Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United StatesJerry C Lee, Tomasz Zdrojewski, Michael J Pencina, et al.
American Heart Journal|September 20, 2015
Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular eventsMin Jung Ko, Yun Jung Kim, Chan Mi Park, et al.
Pharmacoepidemiology and Drug Safety|December 11, 2021
Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapiesSara N Levintow, Kate K Orroth, Alexander Breskin, et al.
Federation Proceedings|December 1, 1986
Direct assessment of renal microcirculatory dynamicsL G Navar, J P Gilmore, W L Joyner, et al.
Clinical Cardiology|June 5, 2021
Prospective evaluation of lipid management following acute coronary syndrome in non-Western countriesAnn Marie Navar, Simon T Matskeplishvili, Miguel Urina-Triana, et al.
American Journal of Physiology. Renal Physiology|November 27, 2015
Vasopressin/V2 receptor stimulates renin synthesis in the collecting ductAlexis A Gonzalez, Flavia Cifuentes-Araneda, Cristobal Ibaceta-Gonzalez, et al.
American Heart Journal|December 12, 2017
Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) projectPaul L Hess, Kevin Kennedy, Michael Cowherd, et al.
Pageof 72